As the Life After Prostate Cancer Diagnosis (LAPCD) project proceeds towards writing up and conclusion we felt that the Clinical Scientific Advisory Group should put formally on record its views about the conduct of the study and its value.
We feel that this programme of work has been of great value in increasing our knowledge of survivorship in prostate cancer and will bring further benefits to prostate cancer patients as the data are disseminated and used. It has been a most productive programme. The publication record is already of very high quality and very substantial. It promises further important publications.
We feel that this programme is in the top 5% of clinical research programmes with which we are familiar and we feel that the investigators, the research teams and the funders should be congratulated on this achievement.
Clinical Scientific Advisory Group – May 2019